Overview

Telbivudine Versus the Combination of Telbivudine and Valtorcitabine in Patients With Chronic Hepatitis B

Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to compare the effectiveness of the combination of valtorcitabine and telbivudine to telbivudine alone in patients with chronic hepatitis B.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis
Collaborator:
Novartis Pharmaceuticals
Treatments:
Telbivudine